Which statin (HMG-CoA reductase inhibitor) can be given with warfarin (anticoagulant)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

All Statins Can Be Safely Used with Warfarin

All statins can be given with warfarin when clinically indicated, as the American Heart Association explicitly states that "use of a statin with warfarin as combination therapy is useful when clinically indicated." 1 The interaction between these medications is modest and manageable through appropriate INR monitoring. 1

Preferred Statins Based on Minimal INR Impact

If minimizing warfarin interaction is a priority, pitavastatin and atorvastatin are the preferred choices, as they have the lowest impact on INR. 1, 2

  • Pitavastatin (4 mg dose) does not appreciably increase INR levels 2
  • Atorvastatin has minimal INR impact according to American Heart Association recommendations 1, 2

Expected INR Changes with Different Statins

All commonly used statins cause modest INR elevations:

  • Simvastatin, atorvastatin, and rosuvastatin increase mean INR by approximately 0.3 points, with peak elevation occurring around 4 weeks after initiation 3, 2, 4
  • Fluvastatin is particularly problematic due to CYP2C9 inhibition, which affects the more potent S-isomer of warfarin 2, 5, 6
  • Rosuvastatin causes an INR increase of 0.30 (95% CI -0.09 to 0.69) 4

Required Monitoring Protocol

Check INR within 1 week of statin initiation and repeat at 4 weeks (peak interaction period). 2

  • More frequent INR monitoring is required after initiating any statin or changing statin dose 1
  • The magnitude of INR change (approximately 0.3) is for most patients of limited clinical relevance 4
  • Continue warfarin at current dose but implement closer monitoring 3

Mechanism of Interaction

The interaction operates through multiple pathways:

  • Protein displacement: Statins (particularly fluvastatin) displace warfarin from plasma protein binding sites, increasing unbound (active) warfarin concentration 2, 5
  • CYP3A4 inhibition: Atorvastatin, rosuvastatin, and simvastatin inhibit this enzyme, reducing warfarin metabolism 2, 5
  • CYP2C9 inhibition: Fluvastatin specifically inhibits this pathway, making it the most problematic statin for warfarin interaction 2, 5, 6

Clinical Pitfalls to Avoid

  • Do not assume all statins are equivalent - fluvastatin's CYP2C9 inhibition makes it particularly problematic compared to other statins 2, 5, 6
  • Do not fail to monitor after statin discontinuation - if warfarin dose was adjusted upward, INR may drop when statin is stopped 2
  • Be aware of case reports of severe outcomes - fatal cerebral hemorrhage has been reported following switch from atorvastatin to simvastatin in warfarin users 7

Special Populations

In patients with diabetes mellitus and nonvalvular atrial fibrillation, the combination of warfarin plus statin showed significantly lower thromboembolic event rates (HR 0.33,95% CI 0.11 to 0.96) compared to warfarin alone, suggesting additional benefit beyond lipid lowering. 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Statin Use with Warfarin: Key Precautions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Managing Simvastatin-Warfarin Interactions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Drug-drug interaction between warfarin and statins: A Danish cohort study.

British journal of clinical pharmacology, 2021

Research

Mechanism of Drug-Drug Interactions Between Warfarin and Statins.

Journal of pharmaceutical sciences, 2016

Research

Probable warfarin-simvastatin interaction.

The Annals of pharmacotherapy, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.